Investor Awareness

HomeAbout Investor AwarenessClient ServicesClient Success StoriesManagement TeamClient ProfilesContact Us

Client Profiles

 

Jaguar Animal HealthJaguar Animal Health, Inc.
Nasdaq: JAGX
www.jaguaranimalhealth.com
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses. Canalevia™ is Jaguar’s lead prescription drug product candidate, intended for the treatment of various forms of diarrhea in dogs. Equilevia™ (formerly referred to as SB-300) is Jaguar’s prescription drug product candidate for the treatment of gastrointestinal ulcers in horses. Canalevia™ and Equilevia™ contain ingredients isolated and purified from the Croton lechleri tree, which is sustainably harvested. Neonorm™ Calf and Neonorm™ Foal are the Company’s lead non-prescription products. Neonorm™ is a standardized botanical extract derived from the Croton lechleri tree. Canalevia™ and Neonorm™ are distinct products that act at the same last step in a physiological pathway generally present in mammals. Jaguar has nine active investigational new animal drug applications, or INADs, filed with the FDA and intends to develop species-specific formulations of Neonorm™ in six additional target species, formulations of Equilevia™ in horses, and Canalevia™ for cats and dogs.

Yahoo Data and NewsCompany Web Site

ICON LEGEND
Yahoo Data and News
 Yahoo Finance Data & News
Company Profile Company Profile (PDF)
Company Web Site Company Web Site

News and Updates

Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
LOS ANGELES, CA--(Marketwired - Aug 7, 2017) - Ritter Pharmaceuticals, Inc. ( NASDAQ : RTTR ) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results for the second quarter ended June 30, 2017. (full story)

Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial
LOS ANGELES, CA--Aug 3, 2017 - Ritter Pharmaceuticals, Inc. ( NASDAQ : RTTR ) (the "Company"), a developer of novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases today announced additional findings and data analysis from its Phase 2b/3 study designed to evaluate lead candidate RP-G28 in subjects with lactose intolerance. (full story)

New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment
SAN FRANCISCO --July 24, 2017 - - Napo Pharmaceuticals, Inc., a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and Jaguar Animal Health, Inc. (JAGX) (Jaguar), announced today the results of a supplemental analysis of the long-term trial of crofelemer (Mytesi®) in patients with chronic HIV-related diarrhea. The analysis revealed a mean decrease of over 70 percent in diarrhea episodes versus baseline and over 50 percent of patients with complete resolution of their diarrhea. The results were reported at the 9th International AIDS Society (IAS) Conference on HIV Science on Wednesday, July 26, 2017 in Paris, France. (full story)

More Articles
 

Upcoming Events

There are no events to display at this time.
Complete Events List
 

Remark HoldingsRemark Holdings, Inc.
NASDAQ: MARK
www.remarkmedia.com
Remark Holdings, Inc. (MARK) owns, operates and acquires innovative digital media properties across multiple verticals that deliver culturally relevant, dynamic content that attracts and engages users on a global scale.  The company leverages its unique digital media assets to target the Millennial demographic, which provides it with access to fast-growing, lucrative markets.  The company is headquartered in Las Vegas, Nevada, with additional operations in Los Angeles, California and in Beijing, Shanghai, Hangzhou and Chengdu, China. For more information, please visit the company's website at www.remarkmedia.com.
Yahoo Data and NewsCompany Web Site

Ritter PharmaceuticalsRitter Pharmaceuticals, Inc.
NASDAQ: RTTR
ritterpharmaceuticals.com
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. We are advancing human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of gut modulation into applications intended to have a meaningful impact on a patient’s health.
Ritter’s leadership team has extensive biotechnology expertise in discovering, developing and commercializing therapeutic products. We have attracted a scientific team comprised of innovative researchers who are world renowned in their knowledge and understanding of the host-microbiome. Combined, our expertise is leading the way in the understanding of the host gut microbiome and the discovery in novel microbiome modulators.
Our lead compound, RP-G28 is currently under development for the treatment of lactose intolerance. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. The product stimulates the growth of lactose-metabolizing bacteria in the colon, which reduces lactose-derived gas production, and thereby mitigates the symptoms of lactose intolerance in the process.
Yahoo Data and NewsCompany Web Site

 

lower_banner

lower_banner-02

  Disclaimer     Financial Glossary

©2013 Investor Awareness, Inc. All rights reserved